SARS-related warning letter
This article was originally published in The Tan Sheet
Executive SummaryFDA issued a warning letter for claims that BetaLoe Immune System Defense Supplement provides "protection for defense against flu, SARS and anthrax," in addition to statements alluding to diseases. Statements include: "Why would a person want to use BetaLoe? Look around you...SARS outbreaks, deadly flu outbreaks, anthrax threats..." The agency says the claims render the product a drug, which requires an NDA...
You may also be interested in...
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.
Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.
The company has reached a broad opioid settlement agreement in principle under which its specialty generics subsidiaries would file for Chapter 11 bankruptcy and Mallinckrodt's branded business would operate separately.